Symptomatic therapy was given in 28% (amifampridine) and 35% (cholinesterase inhibitors), steroids in 32%, non-steroidal immunosuppressants in 12%, exacerbation therapies with IVIG in 21%, while tumor-directed therapy was administered in 91%. The gene discussed is BCHE; the disease is neoplasm.